Chardan Capital assumed coverage on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note published on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $13.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Friday. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a research report on Thursday, September 25th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $9.50.